RHOA and glioblastoma: Inhibiting ROCK2 has been shown to enhance bevacizumab’s effects in GBM by reducing GBM cell viability and migration, primarily through the RhoA/ROCK2 (Rho-kinase-A/Rho-associated coiled-coil forming kinase) pathway, leading to increased apoptosis [99].